Posted by Michael Wonder on 24 Feb 2018
KemPharm announces FDA approval of Apadaz (benzhydrocodone and paracetamol) for the short-term management of acute pain
23 February 2018 - Apadaz is the first pro-drug of hydrocodone/paracetamol to be approved by FDA.
KemPharm announced today that the U.S. FDA approved its new drug application for Apadaz for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Apadaz is an immediate release combination of KemPharm’s prodrug, benzhydrocodone, and paracetamol.
